Whole Genome Sequencing of A(H3N2) Influenza Viruses Reveals Variants Associated with Severity during the 2016⁻2017 Season.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
28 01 2019
Historique:
received: 18 12 2018
revised: 21 01 2019
accepted: 22 01 2019
entrez: 31 1 2019
pubmed: 31 1 2019
medline: 21 6 2019
Statut: epublish

Résumé

Influenza viruses cause a remarkable disease burden and significant morbidity and mortality worldwide, and these impacts vary between seasons. To understand the mechanisms associated with these differences, a comprehensive approach is needed to characterize the impact of influenza genomic traits on the burden of disease. During 2016⁻2017, a year with severe A(H3N2), we sequenced 176 A(H3N2) influenza genomes using next generation sequencing (NGS) for routine surveillance of circulating influenza viruses collected via the French national influenza community-based surveillance network or from patients hospitalized in the intensive care units of the University Hospitals of Lyon, France. Taking into account confounding factors, sequencing and clinical data were used to identify genomic variants and quasispecies associated with influenza severity or vaccine failure. Several amino acid substitutions significantly associated with clinical traits were found, including NA V263I and NS1 K196E which were associated with severity and co-occurred only in viruses from the 3c.2a1 clade. Additionally, we observed that intra-host diversity as a whole and on a specific set of gene segments increased with severity. These results support the use of whole genome sequencing as a tool for the identification of genetic traits associated with severe influenza in the context of influenza surveillance.

Identifiants

pubmed: 30695992
pii: v11020108
doi: 10.3390/v11020108
pmc: PMC6410005
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Horizon 2020
ID : 777363
Pays : International

Références

Nature. 2003 Mar 27;422(6930):428-33
pubmed: 12660783
Bioinformatics. 2009 Jul 15;25(14):1754-60
pubmed: 19451168
N Engl J Med. 2009 Aug 13;361(7):674-9
pubmed: 19564633
J Virol. 2009 Oct;83(19):10309-13
pubmed: 19605485
Genome Biol. 2014 Feb 20;15(2):403
pubmed: 25001293
Hum Vaccin Immunother. 2016 Sep;12(9):2259-68
pubmed: 27166916
PLoS One. 2013 Nov 01;8(11):e79252
pubmed: 24223916
Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12578-12583
pubmed: 29109276
PLoS One. 2010 Apr 23;5(4):e10256
pubmed: 20428231
Clin Infect Dis. 2010 Aug 1;51(3):274-9
pubmed: 20575664
J Med Virol. 2013 Jul;85(7):1250-7
pubmed: 23592041
Nat Commun. 2015 Feb 10;6:6114
pubmed: 25668439
Antivir Ther. 2006;11(8):971-6
pubmed: 17302366
J Infect Dis. 2012 Nov 15;206(10):1504-11
pubmed: 22966122
Nature. 2008 May 29;453(7195):615-9
pubmed: 18418375
Nature. 2006 Jan 19;439(7074):344-8
pubmed: 16327776
Science. 2013 Nov 22;342(6161):976-9
pubmed: 24264991
Lancet Infect Dis. 2016 Jul;16(7):e108-e118
pubmed: 27211899
PLoS One. 2013 Jun 03;8(6):e64734
pubmed: 23755139
Sci Rep. 2015 Mar 16;5:9163
pubmed: 25772381
Nucleic Acids Res. 2011 Mar;39(6):e34
pubmed: 21177643
Virology. 2015 Mar;477:61-71
pubmed: 25659818
PLoS One. 2013 Nov 13;8(11):e80583
pubmed: 24236186
PLoS Pathog. 2017 Oct 12;13(10):e1006650
pubmed: 29023600
Vaccine. 1999 Jul 30;17 Suppl 1:S3-10
pubmed: 10471173
J Mol Model. 2015 Nov;21(11):292
pubmed: 26499499
Influenza Other Respir Viruses. 2013 Nov;7 Suppl 3:18-23
pubmed: 24215378
Microbiol Mol Biol Rev. 2012 Jun;76(2):159-216
pubmed: 22688811
J Virol. 2017 Oct 13;91(21):
pubmed: 28814525
PLoS Pathog. 2017 Jan 31;13(1):e1006194
pubmed: 28141862
J Virol. 2009 Feb;83(4):1718-26
pubmed: 19073746
Elife. 2016 Mar 15;5:e13974
pubmed: 26978794
J Virol. 2016 Jan 06;90(7):3355-65
pubmed: 26739054
Mol Biol Evol. 2016 Jul;33(7):1870-4
pubmed: 27004904
PLoS Pathog. 2012;8(5):e1002730
pubmed: 22693449
PLoS One. 2012;7(4):e35052
pubmed: 22523569
New Microbiol. 2011 Oct;34(4):391-7
pubmed: 22143812
PLoS One. 2013;8(2):e57059
pubmed: 23451145
Lancet. 2009 Aug 8;374(9688):451-8
pubmed: 19643469

Auteurs

Bruno Simon (B)

Virpath, CIRI, Univ Lyon, Inserm U1111 CNRS UMR5308, ENS, UCBL, Faculté de Médecine Lyon Est, 69372 Lyon, France. sib0.smb@gmail.com.
Laboratoire de Virologie, IAI, CBN, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69317 Lyon, France. sib0.smb@gmail.com.

Maxime Pichon (M)

Virpath, CIRI, Univ Lyon, Inserm U1111 CNRS UMR5308, ENS, UCBL, Faculté de Médecine Lyon Est, 69372 Lyon, France. Maxime.PICHON@chu-poitiers.fr.
Laboratoire de Virologie, IAI, CBN, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69317 Lyon, France. Maxime.PICHON@chu-poitiers.fr.
Centre National des Virus Respiratoires, IAI, CBN, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69317 Lyon, France. Maxime.PICHON@chu-poitiers.fr.

Martine Valette (M)

Virpath, CIRI, Univ Lyon, Inserm U1111 CNRS UMR5308, ENS, UCBL, Faculté de Médecine Lyon Est, 69372 Lyon, France. martine.valette@chu-lyon.fr.
Laboratoire de Virologie, IAI, CBN, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69317 Lyon, France. martine.valette@chu-lyon.fr.
Centre National des Virus Respiratoires, IAI, CBN, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69317 Lyon, France. martine.valette@chu-lyon.fr.

Gwendolyne Burfin (G)

Centre National des Virus Respiratoires, IAI, CBN, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69317 Lyon, France. gwendolyne.burfin@chu-lyon.fr.

Mathilde Richard (M)

Department of Viroscience, Erasmus MC, 3000 Rotterdam, The Netherlands.

Bruno Lina (B)

Virpath, CIRI, Univ Lyon, Inserm U1111 CNRS UMR5308, ENS, UCBL, Faculté de Médecine Lyon Est, 69372 Lyon, France. bruno.lina@chu-lyon.fr.
Laboratoire de Virologie, IAI, CBN, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69317 Lyon, France. bruno.lina@chu-lyon.fr.
Centre National des Virus Respiratoires, IAI, CBN, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69317 Lyon, France. bruno.lina@chu-lyon.fr.

Laurence Josset (L)

Virpath, CIRI, Univ Lyon, Inserm U1111 CNRS UMR5308, ENS, UCBL, Faculté de Médecine Lyon Est, 69372 Lyon, France. laurence.josset@chu-lyon.fr.
Laboratoire de Virologie, IAI, CBN, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69317 Lyon, France. laurence.josset@chu-lyon.fr.
Centre National des Virus Respiratoires, IAI, CBN, Groupement Hospitalier Nord, Hospices Civils de Lyon, 69317 Lyon, France. laurence.josset@chu-lyon.fr.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH